지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2016.1
- 수록면
- 1,084 - 1,091 (8page)
이용수
초록· 키워드
오류제보하기
Purpose We sought to investigate the safety and efficacy of gemcitabine, cisplatin, and lapatinib (GCL) as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) planned for radical cystectomy.
Materials and Methods Four cycles of GCL were administered as neoadjuvant therapy for patients with MIBC.
Although initially designed as a phase II efficacy study with a primary endpoint of pathologic complete response at the time of radical cystectomy, the dose selected for investigation proved excessively toxic. A total of six patients were enrolled.
Results The initial four patients received gemcitabine 1,000 mg/m2 intravenously on days 1 and 8 and cisplatin 70 mg/m2 intravenously on day 1 of each 21-day treatment cycle. Lapatinib was administered as 1,000 mg orally daily starting one week prior to the initiation of cycle 1 of gemcitabine and cisplatin (GC) and continuing until the completion of cycle 4 of GC.
These initial doses were poorly tolerated, and the final two enrolled patients received a reduced lapatinib dose of 750 mg orally daily. However, reduction of the lapatinib dose did not result in improved tolerance or drug-delivery, and the trial was terminated early due to excessive toxicity. Grade 3/4 toxicities included diarrhea (33%), nausea/vomiting (33%), and thrombocytopenia (33%).
Conclusion The addition of lapatinib to GC as neoadjuvant therapy for MIBC was limited by excessive treatment-related toxicity. These findings highlight the importance of thorough dose-escalation investigation of combination therapies prior to evaluation in the neoadjuvant setting, as well as the limitations of determination of maximum tolerated dose for novel targeted combination regimens.
목차
등록된 정보가 없습니다.
참고문헌 (25)
참고문헌 신청
Stein JP / 2006 / Radical cystectomy for invasive bladder cancer : long-term results of a standard procedure / World J Urol 24:296~304
Grossman HB / 2003 / Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer / N Engl J Med 349:859~866
Advanced Bladder Cancer(ABC)Meta-analysis Collaboration / 2005 / Neoadjuvant chemotherapy in invasive bladder cancer : update of a systematic review and meta-analysis of individual patient data advanced bladder cancer(ABC)meta-analysis collaboration / Eur Urol 48:202~205
National Comprehensive Cancer Network / NCCN guidelines:bladder cancer
von der Maase H / 2000 / Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer : results of a large, randomized, multinational, multicenter, phase III study / J Clin Oncol 18:3068~3077
Grossman HB / 2003 / Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer / N Engl J Med 349:859~866
Advanced Bladder Cancer(ABC)Meta-analysis Collaboration / 2005 / Neoadjuvant chemotherapy in invasive bladder cancer : update of a systematic review and meta-analysis of individual patient data advanced bladder cancer(ABC)meta-analysis collaboration / Eur Urol 48:202~205
National Comprehensive Cancer Network / NCCN guidelines:bladder cancer
von der Maase H / 2000 / Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer : results of a large, randomized, multinational, multicenter, phase III study / J Clin Oncol 18:3068~3077
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Neoadjuvant Nivolumab plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
Cancer Research and Treatment
2023 .04
-
Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies
Investigative and Clinical Urology
2023 .05
-
Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
Investigative and Clinical Urology
2022 .03
-
What Should We Do, If We Cannot Find The Tumor after Neoadjuvant Therapy?
대한외과학회 학술대회 초록집
2019 .10
-
Recent Advances in the Neoadjuvant Treatment of Breast Cancer
Journal of Breast Cancer
2017 .01
-
An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study
Cancer Research and Treatment
2021 .10
-
Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
Cancer Research and Treatment
2015 .01
-
Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study
Cancer Research and Treatment
2017 .01
-
Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
Cancer Research and Treatment
2021 .10
-
Modifications to Treatment Plan of Rectal Cancer in Response to COVID-19 at the Philippine General Hospital
Annals of Coloproctology
2021 .08
-
Is Neoadjuvant Therapy Needed in Patients with Resectable Pancreatic Cancer?
Gut and Liver
2022 .01
-
Recent Update of Total Neoadjuvant Therapy for Rectal Cancer
대한외과학회 학술대회 초록집
2022 .05
-
Radiological Downstaging with Neoadjuvant Therapy in Unresectable Gall Bladder Cancer Cases
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX
Gut and Liver
2021 .01
-
Case Discussion of Conversion Surgery after Neoadjuvant Therapy: Success and Failure
대한외과학회 학술대회 초록집
2021 .11
-
Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy
Journal of Breast Cancer
2019 .01
-
Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette–Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study
Investigative and Clinical Urology
2024 .05
-
Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer
Annals of Surgical Treatment and Research
2017 .10
이 논문의 저자 정보
최근 본 자료
댓글(0)
0